- Home
- GALT vs MGNX Comparison
GALT vs MGNX Comparison
Compare GALT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- MGNX
- Stock Information
- Founded
- GALT 2000
- MGNX 2000
- Country
- GALT United States
- MGNX United States
- Employees
- GALT N/A
- MGNX N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- MGNX Health Care
- Exchange
- GALT Nasdaq
- MGNX Nasdaq
- Market Cap
- GALT 83.5M
- MGNX 97.2M
- IPO Year
- GALT N/A
- MGNX 2013
- Fundamental
- Price
- GALT $1.31
- MGNX $1.36
- Analyst Decision
- GALT Hold
- MGNX Hold
- Analyst Count
- GALT 1
- MGNX 9
- Target Price
- GALT N/A
- MGNX $5.33
- AVG Volume (30 Days)
- GALT 176.3K
- MGNX 378.7K
- Earning Date
- GALT 05-15-2025
- MGNX 05-13-2025
- Dividend Yield
- GALT N/A
- MGNX N/A
- EPS Growth
- GALT N/A
- MGNX N/A
- EPS
- GALT N/A
- MGNX N/A
- Revenue
- GALT N/A
- MGNX $154,050,000.00
- Revenue This Year
- GALT N/A
- MGNX N/A
- Revenue Next Year
- GALT N/A
- MGNX $45.52
- P/E Ratio
- GALT N/A
- MGNX N/A
- Revenue Growth
- GALT N/A
- MGNX 255.31
- 52 Week Low
- GALT $0.73
- MGNX $0.99
- 52 Week High
- GALT $3.17
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- GALT 48.59
- MGNX 39.88
- Support Level
- GALT $1.22
- MGNX $1.44
- Resistance Level
- GALT $1.36
- MGNX $1.58
- Average True Range (ATR)
- GALT 0.10
- MGNX 0.11
- MACD
- GALT -0.00
- MGNX -0.02
- Stochastic Oscillator
- GALT 29.41
- MGNX 17.65
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.